A phase II study of CCI-779 [temsirolimus] in patients with relapsed or refractory acute myeloid leukemia, acute lymphocytic leukemia, or chronic myeloid leukemia in blastic phase

Trial Profile

A phase II study of CCI-779 [temsirolimus] in patients with relapsed or refractory acute myeloid leukemia, acute lymphocytic leukemia, or chronic myeloid leukemia in blastic phase

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Leukaemia; Myelodysplastic syndromes
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 16 May 2007 Status changed from suspended to completed.
    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top